Patient‐reported symptoms and signs of moderate‐to‐severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial

BACKGROUND: How patients experience the symptoms/signs of psoriasis is highly relevant for assessing treatment response. OBJECTIVES: Compare outcomes with guselkumab, placebo and adalimumab utilizing the novel, validated Psoriasis Symptoms and Signs Diary (PSSD). METHODS: VOYAGE 1 is an ongoing, pha...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Eur Acad Dermatol Venereol
Главные авторы: Papp, K.A., Blauvelt, A., Kimball, A.B., Han, C., Randazzo, B., Wasfi, Y., Shen, Y.‐K., Li, S., Griffiths, C.E.M.
Формат: Artigo
Язык:Inglês
Опубликовано: John Wiley and Sons Inc. 2018
Предметы:
Psoriasis
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6174988/
https://ncbi.nlm.nih.gov/pubmed/29512196
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jdv.14910
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы